Inhibition of the phosphoinositide 3-kinase pathway for the treatment of metastatic metaplastic breast cancer.

Moulder S\textsuperscript{1}, Helgason T\textsuperscript{2}, Janku F\textsuperscript{2}, Wheler J\textsuperscript{2}, Moroney J\textsuperscript{2}, Booser D\textsuperscript{3}, Albarracin C\textsuperscript{4}, Morrow PK\textsuperscript{3}, Atkins J\textsuperscript{2}, Koenig K\textsuperscript{3}, Gilcrease M\textsuperscript{4}, Kurzrock R\textsuperscript{5}.

Author information

\textsuperscript{1}Department of Investigational Cancer Therapeutics (Phase I), The University of Texas, M.D. Anderson Cancer Center, Houston Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston smoulder@mdanderson.org.  
\textsuperscript{2}Department of Investigational Cancer Therapeutics (Phase I), The University of Texas, M.D. Anderson Cancer Center, Houston.  
\textsuperscript{3}Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston.  
\textsuperscript{4}Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston.  
\textsuperscript{5}Department of Hematology and Oncology, UCSD Moores Cancer Center, San Diego, USA.

Abstract

**BACKGROUND:** Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor phosphoinositide 3-kinase (PI3kinase) alterations; thus, therapy with mTor inhibitors may demonstrate activity.

**PATIENTS AND METHODS:** Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated. Mutational analyses [polymerase chain reaction (PCR)-based DNA sequencing method, mass spectrometric detection (Sequenom MassARRAY), or next-generation sequencing] as well as loss of phosphatase and tensin homolog (PTEN) (immunohistochemistry) were performed (archived tissue when available).

**RESULTS:** Twenty-three patients (one of whom was on two separate trials) were treated using temsirolimus-containing regimens: temsirolimus alone (n = 1 patient) or combined with the following: liposomal doxorubicin and bevacizumab (DAT, n = 18); liposomal doxorubicin (DT, n = 1); paclitaxel and bevacizumab (TAT, n = 2); paclitaxel (TT, n = 1); carboplatin and bevacizumab (CAT, n = 1). Response rate [complete response (CR) + partial response (PR)]
was 25% across all regimens; 32% in the anthracycline-based regimens [DAT and DT (CR = 2, PR = 4; N = 19)]. An additional two patients achieved stable disease (SD) ≥6 months [total SD ≥6 months/CR/PR = 8 (33%)]. Molecular aberrations in the PI3K pathway were common: PIK3CA mutation = 6/15 (40%), PTEN mutation = 3/11 (27%), and PTEN loss = 2/11 (18%). A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years). Of the eight patients who achieved SD ≥6 months/CR/PR, all 4 patients with available tissue had a molecular aberration that activate the PIK3CA/Akt/mTOR axis: PIK3CA mutation = 2; PTEN loss = 1; NF2 aberration = 1.

CONCLUSIONS: DAT has activity in MpBCs including complete CRs. Molecular aberrations that can activate the PI3 K/Akt/mTOR axis are common in MpBC.

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

KEYWORDS: bevacizumab; liposomal doxorubicin; metaplastic breast cancer; temsirolimus

PMID: 25878190 DOI: 10.1093/annonc/mdv163

[PubMed - indexed for MEDLINE] Free full text

MeSH Terms, Substances

LinkOut - more resources

---

PubMed Commons

0 comments

PubMed Commons home

How to join PubMed Commons